Alternatives to human blood and blood resources

Vox Sanguinis

Volumn 74, Issue SUPPL. 2, 1998, Pages 21-28

  Prowse, C V ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE;

BIOTECHNOLOGY; BLOOD DONOR; BLOOD TRANSFUSION; CONFERENCE PAPER; PRIORITY JOURNAL; SAFETY;

EID: 0031849464     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05396.x     Document Type: Conference Paper

References (60)

1. Slichter SJ. The Trial to Reduce Alloimmunisation to Platelets (TRAP) Study Group. New England J of Medicine, 1997;337(26):1861-1869.
2. Williamson L, Allain JP. Virus inactivated fresh frozen plasma. Vox Sang. 1995;69:159-165.
3. World patent 96/39818. Treating Red Blood Cell Solutions with Anti-Viral Agents. Cerus Corporation, 1996.
4. Norfolk DR, Williamson L. Leucodepletion of blood products by filtration. Blood Reviews, 99;8-14.
5. Kruskall MS, AuBuchon JP. Making Land-steiner's Discovery Superfluous: Safety and Economic Implications of a Universal Group O Red Blood Cell Supply. Transfus. Sci., 1997;18:613-620.
6. Spanos T, Ladis V, Palamidou F, Papassotiriou I, Banagi A, Premetis E, Kattamis C. The Impact of neocyte Transfusion in the Man agement of Thalassaeia. Vox Sang. 1996;70:217-223.
7. Keipert PE, Gomez GL, Gonzales A, Mac-Donald VW, Hess JR, Winslow RM. Diaspirin cross-linked hemoglobin: Tissue distribution and long-term excretion after exchange transfusion. J. Lab. Clin. Med. 1994;123(5):701-711.
8. Hess JR. Blood Substitutes. Seminars in Hematology, 1996;33(4):369-378.
9. Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman J, Isaacs ST, Wollowitz S, Corash L. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion, 1997;37:423-435.
10. Goldman M, Delage G. The role of leuko-depletion in control of transfusion-transmitted disease. Transfusion Med. Rev. 1995;IX:9-19.
11. Bessos H, Seghatchian J. Platelet transfusion: Evolving alternative therapeutic products. Platelets 1997;8:407-446.
12. World patent WO 97/29128. GPIb-Lipid Complex and Uses thereof. Green Cross, 1997.
13. Mannucci. DDAVP: twenty years after. Thromb Haemostas 1997;78:958
14. Leonardi G. Cardiac surgery: the benefits of aprotinin. Biomedical Progress 1995;8:8-12.
15. Jackson MR, MacPhee MJ, Drohan WN, Alving BM. Fibrin sealant: current and potential clinical applications. Blood Coagulation and Fibrinolysis, 1996;7:737-746.
16. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, Bech R, Hedner U, Schiff ER. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study: Gastroenterol. 1997;113(6):1930-1937.
17. McClelland DBL. Human Albumin Solutions. BMJ, 1990;300:35-37.
18. Schneider P. Artificial blood substitutes. Transfus Sci. 1992;13:357-370.
19. Spivak JL. Recombinant human erythropoietin and its role in transfusion medicine. Transfusion, 1994;34(1):1-4.
20. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-mrtHuG-CSF): the first ten years. Blood 1996:88:1907-1929.
21. Hamblin T. Cytokines to Reduce Platelet Transfusions: Non-TPO Cytokines. Transfusion Science, 1997;18(1):121-128.
22. Kaushansky K. Thrombopoietin: The Primary Regulator of Platelet Production. Blood, 1995;86(2):419-431.
23. Braisted A. Hormone peptidomimetics: seeing double. Nature Biotechnology, 1997;15:1244-1245.
24. Roddie PH, Ludlam CA.: Recombinant coagulation factors. Blood Reviews 1997;11:169-172.
25. Montano RF, Romano EL. Human monoclonal anti-Rh antibodies produced by human-mouse heterohybridomas express the Gal α1-3 Gal epitope. Hum. Antibod. Hybridomas, 1994;5-3-4:152-156.
26. Velander WH, Lubon HK, Drohan WN. Transgenic Livestock as Drug Factories. Sc. Amer. 1997;January:70-74.
27. Campbell KHS, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature, 1996;380;64-06.
28. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-receptor blockade with Daclizumab to prevent acute rejection in renal transplantation. New Eng. J. Med. 1998;338(3):161.
29. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, Woods R, Bansal G, Gouchenour D, Tsae E, Hall WC, Young JF. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect. Dis. 1997;175(5):1215-1224.
30. - Volunteers. Blood, 1995;86(5):1701-1709.
31. World patent WO 94/16730. Human monoclonal antibodies to Cytomegalovirus. Sandoz, 1994.
32. World patent 94/11495. Production of human monoclonal antibodies specific for hepatitis B. Sandoz Ltd 1994.
33. Gunthard HF, Gowland PL, Schupbach J, Fung MSC, Boni J, Liou RS, Chang NT, Grob P, Graepel P, Braun DG, Luthy R. A Phase I/IIA Clinical Study with a Chimeric Mouse-Human Monoclonal Antibody to the V3 Loop of Human Immunodeficiency Virus Type 1 gp120. J. Infectious Diseases, 1994;170:1384-1393.
34. US patent 5,506,132 Human antibodies against Varicella zoster. Sandoz 1996
35. Mouthon L, Kaveri SV, Spalter SH. Mechanism of action of intravenous immunoglobulins in immune-mediated diseases. Clin. Exp. Immunol. 1996;104:3-9.
36. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. Thromb. Haemost. 1998;79:134-139.
37. Delgado C, Francis GE, Fisher D. The uses and properties of PEG-linked proteins. Crit Rev in Threapeutic Drug Carrier Systems 1992;9:249-304
38. Imura Y, Stassen JM, Kurokawa T, Iwasa S, Lijnen HR, Collen D. Thrombolytic and Pharmacokinetic Properties of an Immuno-conjugate of Single-Chain Urokinase-Type Plasminogen Activator (u-PA) and a Bispecific Monoclonal Antibody Against Fibrin and Against u-PA in Baboons. Blood, 1992;79(9):2322-2329.
39. US Patent 5,571,708. Thrombin-activatable plasminogen activator. Bristol-Myers-Squibb, 1997
40. Voorberg J, van Stempvoort G, Klaasse Bos JM, Mertens K, van Mourik JA, Donath MJSH. Enhanced thrombin sensitivity of a factor-VIII heparin cofactor II-hybrid. J. Biol. Chem., 1996;271:20985-20988.
41. Lubin IM, Healey JF, Scandella D, Runge MS, Lollar P. Elimination of a Major Inhibitor Epitope in Factor VIII*. J. Biol. Chem. 1994;269:8639-8641.
42. Kane WH, Ortel TL. Chimeric blood coagulation proteins. US Patent 5,587,310. 1996.
43. Scandella D, Mattingly M, Prescott R. A Recombinant Factor VIII A2 Domain Polypeptide Quantitatively Neutralizes Human Inhibitor Antibodies That Bind to A2. Blood, 1993;82:1767-1775.
44. Weiss RA. Transgenic pigs and virus adaptation. Nature 1998;391:327-328.
45. Ricketts MN, Cashman NR, Stratton EE, El Saadany S. Is Creutzfeldt Jakob Disease Transmitted in Blood? Emerging Infectious Diseases. 1997;3:155-163.
46. Prowse CV, MacGregor IR: Neoantigens and antibodies to factor VIII. Blood Reviews 1998; - in press.
47. Briet E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung R, Rocino A, Addiego J, Lorenzo JI, Pabinger I. High Titer Inhibitors in Severe Haemophilia A: A Meta-analysis Based on Eight Long-term Follow-up Studies concerning Inhibitors Associated with Crude or Intermediate Purity Factor VIII Products. Thromb. Haemost. 1994;73:162-164.
48. Raanani P, Dazzi F, Sohal J, Szydlo RM, van Rhee F, Reiter A, Lin F, Goldman JM, Cross NCP. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. British J of Haematology, 1997;99:945-950.
49. Dale DC, Liles WC, Price TH. Annotation: Renewed interest in granulocyte transfusion therapy. British J of Haematology, 1997;98:497-501.
50. Cairo MS, Wagner JE. Placental and/or Umbilical Cord Blood: An Alternative Source of Hematopoietic Stem Cells for Transplantation. Blood, 1997;90(12):4605-4678.
51. Rice A, Ripoche J, Reiers J. Hematopoietic stem cell expansion. Transfus Sci 1997;18:263-275.
52. Turner ML, McClelland DBL, Franklin IM. Haemopoietic progenitor cell harvesting, processing and storage: global regulation to ensure the quality of products for patients. British J of Haematology, 1997;99:715-718.
53. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995;333:1038.
54. Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene modified virus-specific T lymphocytes to control Epstein-Bar-virus related lympho-proliferation. Lancet 1995;345:9-13.
55. Lieberman J, Skolnik PR, Parkerson GR, Fabry JA, Landry B, Bethel J, Kagan, J, and the DATRI 006 studt team. Safety of autologous, ex-vivo expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood 1997;90:2196-2206
56. Banchereau J. Dendritic cells; therapeutic potential. Transfus Sci. 1997;18:313-326.
57. Oberling F. Monocyte/Macrophages as effector cells in cancer immunotherapy. Transfus Sci. 1997;18:243-250.
58. Halverson DC, Schwartz GN, Carter C, Gress RE, Fowler DH. In vitro generation of allospecific human CD8 T cells of Tc1 and Tc2 phenotype. Blood 1997;90:2089-2096
59. Cornetta K, Fan Y: Retroviral therapy in haematopoietic diseases. J. clin. Apheresis 1997;12:187-193.
60. Peault B, Charbord P. Gene transfer into human haematopoietic stem cells. Transfus Sci. 1997,18:291-311.